A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A

NCT03020160 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A

Interventions

DRUG: Emicizumab

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]